Iovance Biotherapeutics Quarterly Income Statement
NASDAQ: IOVAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Iovance Biotherapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Iovance Biotherapeutics generated $99.3 million in revenue, up 65.7% from the same quarter a year earlier. Iovance Biotherapeutics reported a net loss of $47.3 million, compared with a loss of $111.7 million a year earlier. Gross margin was 56.1% (up from 18.5%) and operating margin -52.3%.
Diluted earnings per share came in at -$0.11.
Summary generated from market data by MetaCap's automated system. Methodology
Iovance Biotherapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 99.31M | 71.43M | 86.77M | 67.45M | 59.95M | 49.32M | 73.69M | 58.55M | 31.11M | 715.00K | 482.00K | 469.00K |
| Revenue growth (YoY) | +65.65% | +44.82% | +17.74% | +15.20% | +92.73% | +6798.46% | +15189.21% | +12385.07% | +12969.75% | — | — | — |
| Cost of Revenue | 43.59M | 42.50M | 43.11M | 38.48M | 48.88M | 42.72M | 37.79M | 31.52M | 31.37M | 7.26M | -5.36M | 4.34M |
| Gross Profit | 55.72M | 28.93M | 43.66M | 28.98M | 11.07M | 6.61M | 35.91M | 27.04M | -262.00K | -6.55M | 5.84M | -3.87M |
| Operating Expenses | 107.62M | 109.97M | 117.12M | 123.88M | 124.84M | 127.83M | 122.48M | 116.10M | 101.65M | 111.18M | 127.09M | 114.49M |
| Research & Development | 58.85M | 62.49M | 71.20M | 75.17M | 77.93M | 75.97M | 71.01M | 67.04M | 62.08M | 79.78M | 76.59M | 87.53M |
| Operating Income | -51.91M | -81.04M | -73.46M | -94.90M | -113.77M | -121.22M | -86.58M | -89.07M | -101.91M | -117.72M | -121.26M | -118.36M |
| Pretax Income | -48.69M | -79.71M | -71.72M | -93.66M | -109.67M | -118.00M | -77.00M | -85.06M | -98.56M | -114.38M | -118.14M | -115.00M |
| Income Tax | -1.37M | -665.00K | 184.00K | -2.40M | 1.99M | -1.84M | 1.56M | -1.52M | -1.46M | -1.41M | -1.76M | -1.24M |
| Net Income | -47.31M | -79.05M | -71.90M | -91.25M | -111.66M | -116.16M | -78.56M | -83.54M | -97.10M | -112.98M | -116.38M | -113.76M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.11 | -0.19 | -0.15 | -0.25 | -0.33 | -0.36 | -0.24 | -0.28 | -0.34 | -0.42 | -0.46 | -0.46 |
| EPS (Diluted) | -0.11 | -0.19 | — | — | -0.33 | -0.36 | -0.24 | -0.28 | -0.34 | -0.42 | -0.46 | -0.46 |
| Shares Outstanding (Basic) | 450.19K | 418.51K | — | 364.04K | 334.51K | 322.87K | — | 303.27K | 284.82K | 266.22K | — | 245.82K |
| Shares Outstanding (Diluted) | 450.19K | 418.51K | — | — | 334.51K | 322.87K | — | 303.27K | 284.82K | 266.22K | — | 245.82K |
| EBITDA | -48.12M | -78.22M | -69.74M | -91.71M | -110.37M | -118.65M | -83.30M | -86.07M | -98.91M | -114.74M | -118.31M | -115.46M |
| Gross Margin | 56.10% | 40.50% | 50.32% | 42.96% | 18.47% | 13.40% | 48.72% | 46.17% | -84.00% | -915.52% | 1211.41% | -825.37% |
| Operating Margin | -52.26% | -113.46% | -84.66% | -140.69% | -189.78% | -245.76% | -117.48% | -152.11% | -327.63% | -16464.62% | -25156.85% | -25236.89% |
| Net Margin | -47.64% | -110.66% | -82.87% | -135.28% | -186.25% | -235.51% | -106.60% | -142.67% | -312.16% | -15800.84% | -24145.02% | -24255.86% |
This table shows 12 quarterly periods of Iovance Biotherapeutics's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow IOVA's reporting calendar. What is a income statement?